Navigation Links
Review offers insight on managing surgical patients who are taking new drugs to prevent blood clots
Date:4/28/2014

New oral anticoagulant drugs that treat and prevent clots offer a much-needed alternative to warfarin, which has been used for more than 6 decades and has serious shortcomings. A new article published in BJS (British Journal of Surgery) gives an overview of the major clinical trials and recommendations related to these new agents and will serve as a practical guide for their use in patients who require planned or emergency surgery.

Warfarin has been the drug of choice to control blood clots in a variety of patients, including people with certain types of irregular heartbeats, people with prosthetic heart valves, and people who have suffered heart attacks. Unfortunately, warfarin has serious side-effects, requires frequent monitoring to reduce the risk of bleeding, and has interactions with multiple drugs and foods. New oral anticoagulant drugsApixaban, Dabigatran, and Rivaroxaban offer safer alternatives to warfarin, but there are currently no markers for measuring activity levels of the drugs and there are no antidotes to reverse or neutralize their effects.

Aida Lai, MBChB, of the North Bristol NHS Trust in the UK, and her colleagues searched the medical literature and analysed studies published between January 2000 and January 2014 that reported on the use of new oral anticoagulant drugs. "As these drugs are still relatively new in the market, knowledge about how they work and their associated bleeding risks are still limited in the medical and surgical community," said Dr Lai. "Our review covers recommendation for the discontinuation of new oral anticoagulant drugs before surgical procedures and resuming of these drugs after procedures." The review also notes that because the drugs are eliminated by the kidneys, they require dose reductions dependent on a patient's kidney function. Also, new oral anticoagulants are not recommended in patients with severe liver dysfunction. And because the three drugs have somewhat different properties, one of the drugs may be better suited to a particular patient than the others.

"It is anticipated that in the near future these drugs would replace warfarin to a large extent," said Dr Lai. "Therefore our article is highly relevant to surgeons and any medical professional treating patients on these drugs."


'/>"/>

Contact: Evelyn Martinez
sciencenewsroom@wiley.com
201-748-6358
Wiley
Source:Eurekalert

Related medicine news :

1. McCullers reviews influenza, bacterial superinfections in Nature Reviews Microbiology
2. Internists review progress, challenges and opportunities
3. Do patient decision support interventions lead to savings? A systematic review
4. CU-built software uses big data to battle forgetting with personalized content review
5. PowerSteering from Upland Software Earns High Marks in Review by GetApp
6. Vision Without Glasses: Review Released by ReviewsGod.com
7. Total Balance Men’s: Review Released for Xtend-Life’s Comprehensive Dietary Supplement for Men
8. Workout Finishers Review – How Workout Finishers Helps People To Get A Fit Shape – Vinaf.com
9. 14 Day Rapid Fat Loss Plan Review–How To Get Rid Of Fat With 14 Day Rapid Fat Loss – Vinaf.com
10. The Cleft Palate–craniofacial Journal Marks 50 Years of Research With an Ethical Review
11. Regenstrief and IU review finds lack of delirium screening in the emergency department
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... Trusted debt-reduction firm CreditAssociates, LLC has announced two ... in excess of $835 million in resolved debt for its clients. , Credit card ... of the categories of debt settled by the company. With more than a decade ...
(Date:9/19/2017)... ... September 19, 2017 , ... Arizona-based ... as the President of its HealthBI division. McFarland will grow the organization’s ... , “Scott is a utility player who balances his day as a ...
(Date:9/19/2017)... Hill, CT (PRWEB) , ... September 19, 2017 ... ... support, today announced the winners of the Entrepreneur Innovation Awards (EIA), held this ... all of whom are Connecticut-based companies and entrepreneurs, presented their innovative project ideas ...
(Date:9/19/2017)... ... September 19, 2017 , ... MelaKids, a Laredo-based company, has introduced a new ... we’re born, Nature gives us a full supply of melanin – in the back ... this natural glare-reducing pigment; however, around the age of thirty, we develop a yellow-brown ...
(Date:9/19/2017)... ... September 19, 2017 , ... Presenting its annual ... (SPBA) hosted “Expanding Your Success” with an educational emphasis. , The three-day ... best practices for third party administrators (TPAs) related to health plan management and ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
(Date:9/1/2017)...  Bayer will present the latest research from across its ... (ESMO) 2017 Congress, September 8-12 in Madrid, Spain ... clinical data on Bayer,s marketed portfolio and late-stage compounds as ... "We value the opportunity to ... at ESMO," said Carsten Brunn , Head of Pharmaceuticals, ...
(Date:8/29/2017)... 29, 2017 In a move that promises ... compliance for veterinary practices of all sizes, Cubex LLC ... that makes TITAN,s expertise in physical security, drug diversion ... clients nationally. ... controlled substances is at risk today," said TITAN founder ...
Breaking Medicine Technology: